Stocks to buy in 2026 for long term: Dr Lal PathLabs, IDFC First Bank among 5 stocks that could give 10-30% return

Brokerages continue to remain constructive on select stocks across the healthcare, banking, defence, pharmaceuticals and specialty chemicals sectors, backed by improving earnings prospects and strong business fundamentals.

We have collated a list of recommendations from top brokerage firms from ETNow and other sources:

Nuvama on Dr Lal PathLabs: Buy| Target Rs 2140 (vs Rs 1900)| LTP Rs 1756| Potential Upside 21%

Nuvama has reiterated its 'Buy' rating on Dr Lal PathLabs and raised the target price to Rs 2,140 from Rs 1,900, implying a potential upside of 21% from the current market price of Rs 1,756.

Nuvama on IDFC First Bank: Upgrade to buy from hold| Target Rs 95| LTP Rs 80| Potential Upside 18%

Nuvama has upgraded IDFC First Bank to 'Buy' from 'Hold' and assigned a target price of Rs 95, indicating a potential upside of 18% from the current market price of Rs 80.

AnandRathi on Jubilant Ingrevia: Buy| Target Rs 980| LTP Rs 725| Potential Upside 35%

Anand Rathi has maintained a 'Buy' rating on Jubilant Ingrevia with a target price of Rs 980, suggesting a potential upside of 35% from the current market price of Rs 725.

AnandRathi on Hindustan Aeronautics: Buy| Target Rs 5431| LTP Rs 4569| Potential Upside 18%

Anand Rathi has reiterated its 'Buy' recommendation on Hindustan Aeronautics with a target price of Rs 5,431, implying a potential upside of 18% from the current market price of Rs 4,569.

Emkay Global on Granules India: Buy| Target Rs 950| LTP Rs 833| Potential Upside 14%

Emkay Global has maintained its 'Buy' rating on Granules India and set a target price of Rs 950, indicating a potential upside of 14% from the current market price of Rs 833.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)